10.8 mg
Trade Name
Zoladex LA
Implant, in pre-filled syringe
Request Type
Registration
Drug Type
New Drug
Approval Date
SFDA Approved Use
Treatment of prostate cancer in the following settings:
• In the treatment of metastatic prostate cancer where Goserelin acetate has demonstrated comparable survival benefits to surgical castrations
• In the treatment of locally advanced prostate cancer, as an alternative to surgical castration where Goserelin acetate has demonstrated comparable survival benefits to an anti-androgen
• As adjuvant treatment to radiotherapy in patients with high-risk localised or locally advanced prostate cancer where Goserelin acetate has demonstrated improved disease-free survival and overall survival
• As neo-adjuvant treatment prior to radiotherapy in patients with high risk localised or locally advanced prostate cancer where Goserelin acetate has demonstrated improved disease-free survival
• As adjuvant treatment to radical prostatectomy in patients with locally advanced prostate cancer at high risk of disease progression where
Goserelin acetate has demonstrated improved disease-free survival
Goserelin acetate 10.8 mg is indicated in the management of oestrogen-receptor (ER) positive early and advanced breast cancer in pre and peri menopausal women.
• In the treatment of metastatic prostate cancer where Goserelin acetate has demonstrated comparable survival benefits to surgical castrations
• In the treatment of locally advanced prostate cancer, as an alternative to surgical castration where Goserelin acetate has demonstrated comparable survival benefits to an anti-androgen
• As adjuvant treatment to radiotherapy in patients with high-risk localised or locally advanced prostate cancer where Goserelin acetate has demonstrated improved disease-free survival and overall survival
• As neo-adjuvant treatment prior to radiotherapy in patients with high risk localised or locally advanced prostate cancer where Goserelin acetate has demonstrated improved disease-free survival
• As adjuvant treatment to radical prostatectomy in patients with locally advanced prostate cancer at high risk of disease progression where
Goserelin acetate has demonstrated improved disease-free survival
Goserelin acetate 10.8 mg is indicated in the management of oestrogen-receptor (ER) positive early and advanced breast cancer in pre and peri menopausal women.